MediWound

CompanyIsrael

MediWound develops one asset, in phase 2 (EscharEx in venus leg ulcers). Mostly protein or enzyme; based in Israel.

1
Asset
Furthest stage
Phase 2
1
Trial
1
Signal

Pipeline

1
  • EscharEx

    Bromelain-based proteolytic enzymes remove devitalized tissue from chronic wounds through enzymatic debridement.

    Phase 2, Protein or enzyme, venus leg ulcers

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Trials1
  • Signals1

Intelligence